Kodiak Sciences Inc. (NASDAQ:KOD - Get Free Report) traded up 5.1% during mid-day trading on Tuesday . The company traded as high as $3.98 and last traded at $3.90. 216,909 shares changed hands during mid-day trading, a decline of 37% from the average session volume of 345,457 shares. The stock had previously closed at $3.71.
Wall Street Analyst Weigh In
Separately, HC Wainwright reissued a "neutral" rating and issued a $3.00 price target on shares of Kodiak Sciences in a research report on Monday, March 31st.
Check Out Our Latest Research Report on Kodiak Sciences
Kodiak Sciences Stock Up 13.8%
The stock has a market cap of $234.25 million, a P/E ratio of -1.22 and a beta of 2.28. The firm's 50-day moving average is $3.83 and its two-hundred day moving average is $4.75.
Kodiak Sciences (NASDAQ:KOD - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($1.09) EPS for the quarter, missing analysts' consensus estimates of ($0.89) by ($0.20). Analysts anticipate that Kodiak Sciences Inc. will post -3.45 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Kodiak Sciences
A number of institutional investors have recently modified their holdings of KOD. Price T Rowe Associates Inc. MD grew its stake in shares of Kodiak Sciences by 10,982.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,268,509 shares of the company's stock worth $12,622,000 after acquiring an additional 1,257,063 shares during the last quarter. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Kodiak Sciences in the fourth quarter worth $11,338,000. Boxer Capital Management LLC acquired a new stake in shares of Kodiak Sciences in the fourth quarter worth $9,950,000. Point72 Asset Management L.P. acquired a new stake in shares of Kodiak Sciences in the fourth quarter worth $5,211,000. Finally, Silverarc Capital Management LLC grew its stake in shares of Kodiak Sciences by 100.0% in the fourth quarter. Silverarc Capital Management LLC now owns 1,000,000 shares of the company's stock worth $9,950,000 after acquiring an additional 500,000 shares during the last quarter. Institutional investors own 89.06% of the company's stock.
Kodiak Sciences Company Profile
(
Get Free Report)
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
Featured Articles
Before you consider Kodiak Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list.
While Kodiak Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
